Efficacy and Safety of Baricitinib in Sjogren's Syndrome

NCT05016297 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

87

Enrollment

OTHER

Sponsor class

Conditions

Sjogren's Syndrome

Interventions

DRUG: Baricitinib
DRUG: Hydroxychloroquine

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]